Initiation of global Phase III clinical study by Merck KGaA of the Therapeutic Cancer Vaccine Stimuvax® in Patients with Breast Cancer
London, UK 22nd June 2009 – Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce initiation of global Phase III clinical study by Merck KGaA of the therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. The STRIDE(a) study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer.
Stimuvax® is a liposomal peptide vaccine against the tumour-associated protein MUC1. The vaccine was developed by Oncothyreon (formerly Biomira) under a portfolio of patents licensed by CRT, following Cancer Research UK-funded investigations led by Prof Joyce Taylor-Papadimitriou at Guy’s Hospital, London. Stimuvax was the first investigational cancer vaccine to enter Phase III clinical testing in NSCLC with the February 2007 launch of the STARTb study, which will involve more than 1,300 patients with unresectable stage III NSCLC, who were stable or responding after chemoradiotherapy.
You can find out more about this new study by reading Merck KGaA announcement here
|
